Pharmathen completed the acquisition of CBL Patras.

Pharmathen, a complex drug delivery and formulation developer, completed the acquisition of CBL Patras, a vertically integrated peptides developer and US-FDA approved manufacturer. Financial terms were not disclosed. "We remain committed to our vision to improve people’s lives through innovation and access to affordable medicines. This acquisition is expected to unlock substantial commercial and R&D pipeline synergies for both companies and expand the products and services that we offer to our customers. By continuously fostering the growth of our teams, we will create one of the most successful centers of innovation in our sector, supporting the further access to a market that is expected to grow exponentially in the years ahead. This milestone underpins Partners Group’s strong commitment to invest into and continuously advance Pharmathen’s sustainable growth since acquiring Pharmathen in January 2022," Dimitris Kadis, Pharmathen CEO.